To assess if the MVA-ZIKV vaccine was as efficacious against ZIKV as reported by Perez et al.14, adult IFNAR-/- mice were immunized with a single dose of 108 PFU of MVA-ZIKV by the IM route, and 28-days later, challenged subcutaneously (SC) with ZIKV (103 PFU, Fig. 3A) and compared to control IFNAR-/- mice (PBS followed by PBS 28-days later) or PBS + ZIKV (PBS followed by ZIKV infection 28-days later) or MVA + ZIKV (empty MVA vector followed by ZIKV infection 28-days later). The gene discussed is IFNAR1; the disease is Zika virus infectious disease.